IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys.
The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates in different stages of development.
This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms.
Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.
Explore Report at: www.psmarketresearch.com/market-an…ipeline-analysis
Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine.
Explore Report Sample at: www.psmarketresearch.com/market-an…is/report-sample
Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: